Development Status
ZYL-314
Early Alzheimer’s Disease
Mild Cognitive Impairment (MCI)
Program
Discovery
Preclinical
Phase 1
Phase 2
The development of ZYL-314 has opened up the possibility of a rich development platform.
For ZYL-314 itself, possibilities include different formulations, dose-ranges, and timing of administration. These can be targeted to several different indications. Additionally, we have a series of patent-protected combinations with ZYL-314 which further increase the possible range of treatment options.
Taken together the Zylorion platform offers a huge range of clinical possibilities based upon BDNF / TrkB enhancement of neuroplasticity.
Development Status
ZYL-314
Early Alzheimer’s Disease
Mild Cognitive Impairment (MCI)
Discovery
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
ZYL-315
Chronic Brain Injury / CTE
Post-traumatic Stress Disorder (PTSD)
Discovery
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
ZYL-316
Chronic Migraine / Cluster Headache
Chronic Neuropathic Pain
Discovery
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
ZYL-318
Social Anxiety Disorder
Major Depressive Disorder (MDD)
Discovery
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
ZYL-320
Parkinson’s Disease
Multiple Sclerosis
Discovery
Preclinical
Phase 1
Phase 1
Phase 2
Phase 2
